Novel Anti-Infective Treatments
We are committed to delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections. We are developing Ibrexafungerp (formerly SCY-078), the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family, for the treatment of several serious fungal infections, including vulvovaginal candidiasis (VVC), invasive candidiasis, invasive aspergillosis and refractory invasive fungal infections.
A Versatile Anti-Infective
